Soluble amyloid-β levels and Late-Life Depression

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2547-2554

  Osorio, Ricardo S ^a   Gumb, Tyler ^a   Pomara, Nunzio ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; ApoE4; A 42; Biomarkers; Cerebrospinal fluid; Dementia; Elderly; Late Life depression; Plasma

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID; DEMENTIA; DEPRESSION; HUMAN; LATE LIFE DEPRESSION; MULTIINFARCT DEMENTIA; PATHOGENESIS; PRIORITY JOURNAL; RELIABILITY; SLEEP WAKING CYCLE; SYSTEMATIC REVIEW; AGED; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; MAJOR DEPRESSION; MALE; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS;

EID: 84903725263     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990502     Document Type: Article

References (115)

1. Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 2003; 58: 249-65.
2. Burns RA, Butterworth P, Windsor TD, Luszcz M, Ross LA, Anstey KJ. Deriving prevalence estimates of depressive symptoms throughout middle and old age in those living in the community. Int Psychogeriatr 2012; 24: 503-11.
3. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62: 1097-106.
4. Jorm AF. Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span. Psychol Med 2000; 30: 11-22.
5. Giordana JY, Roelandt JL, Porteaux C. [Mental Health of elderly people: The prevalence and representations of psychiatric disorders]. Encephale 2010; 36: 59-64.
6. Wu Z, Schimmele CM, Chappell NL. Aging and late-life depression. J Aging Health 2012; 24: 3-28.
7. Alexopoulos GS, Buckwalter K, Olin J, Martinez R, Wainscott C, Krishnan KR. Comorbidity of late life depression: an opportunity for research on mechanisms and treatment. Biol Psychiatry 2002; 52: 543-58.
8. Crocco EA, Castro K, Loewenstein DA. How late-life depression affects cognition: neural mechanisms. Curr Psychiatry Rep 2010; 12: 34-8.
9. Reynolds CF, III, Kupfer DJ. Depression and aging: a look to the future. Psychiatr Serv 1999; 50: 1167-72.
10. Baldwin RC, Tomenson B. Depression in later life. A comparison of symptoms and risk factors in early and late onset cases. Br J Psychiatry 1995; 167: 649-52.
11. Brodaty H, Luscombe G, Parker G, et al. Early and late onset depression in old age: different aetiologies, same phenomenology. J Affect Disord 2001; 66: 225-36.
12. Krishnan KR, Hays JC, Tupler LA, George LK, Blazer DG. Clinical and phenomenological comparisons of late-onset and earlyonset depression. Am J Psychiatry 1995; 152: 785-8.
13. Van den Berg MD, Oldehinkel AJ, Bouhuys AL, Brilman EI, Beekman AT, Ormel J. Depression in later life: three etiologically different subgroups. J Affect Disord 2001; 65: 19-26.
14. Alexopoulos GS, Kiosses DN, Klimstra S, Kalayam B, Bruce ML. Clinical presentation of the "depression-executive dysfunction syndrome" of late life. Am J Geriatr Psychiatry 2002; 10: 98-106.
15. Wiener P, Alexopoulos GS, Kakuma T, Meyers BS, Rosenthal E, Chester J. The limits of history-taking in geriatric depression. Am J Geriatr Psychiatry 1997; 5: 116-25.
16. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry 2008; 165: 238-44.
17. Schweitzer I, Tuckwell V, Ames D, O'Brien J. Structural neuroimaging studies in late-life depression: a review. World J Biol Psychiatry 2001; 2: 83-8.
18. Hickie I, Naismith S, Ward PB, et al. Reduced hippocampal volumes and memory loss in patients with early-and late-onset depression. Br J Psychiatry 2005; 186: 197-202.
19. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin MB, Bennett B. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biological Psychiatry 1995; 37: 151-60.
20. Hickie I, Scott E, Wilhelm K, Brodaty H. Subcortical hyperintensities on magnetic resonance imaging in patients with severe depression--a longitudinal evaluation. Biol Psychiatry 1997; 42: 367-74.
21. Naismith SL, Hickie IB, Turner K, et al. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors. J Clin Exp Neuropsychol 2003; 25: 866-77.
22. Kiloh LG. Pseudo-dementia. Acta Psychiatrica Scandinavica 1961; 37: 336-51.
23. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012; 69: 493-8.
24. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, metaanalysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530-8.
25. Lee GJ, Lu PH, Hua X, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's diseaserelated regions. Biol Psychiatry 2012; 71: 814-21.
26. Wright SL, Persad C. Distinguishing between depression and dementia in older persons: neuropsychological and neuropathological correlates. J Geriatr Psychiatry Neurol 2007; 20: 189-98.
27. Weisenbach SL, Boore LA, Kales HC. Depression and cognitive impairment in older adults. Curr Psychiatry Rep 2012; 14: 280-8.
28. Heun R, Kockler M, Ptok U. Depression in Alzheimer's disease: is there a temporal relationship between the onset of depression and the onset of dementia? Eur Psychiatry 2002; 17: 254-8.
29. Ganguli M, Du Y, Dodge HH, Ratcliff GG, Chang CC. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch Gen Psychiatry 2006; 63: 153-60.
30. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry 2001; 35: 776-81.
31. Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS. Depressive symptoms and cognitive decline in nondemented elderly women: a prospective study. Arch Gen Psychiatry 1999; 56: 425-30.
32. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry 2006; 63: 273-9.
33. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurol 2010; 75: 35-41.
34. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurol 2010; 75: 27-34.
35. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31(8): 1275-83.
36. Amieva H, Le GM, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492-8.
37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurol; 34: 939-44.
38. Cummings JL, Victoroff JI. Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry, Neuropsychology and Behavioral Neurology 1990; 3: 140-58.
39. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurol 1991; 41: 479-86.
40. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991; 82: 239-59.
41. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurol 2002; 58: 1791-800.
42. Pomara N, Murali DP. Does increased platelet release of Abeta peptide contribute to brain abnormalities in individuals with depression? Med Hypotheses 2003; 60: 640-3.
43. Kuo YM, Kokjohn TA, Kalback W, et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 2000; 268: 750-6.
44. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets Are the Primary Source of Amyloid [beta]-Peptide in Human Blood. Biochemical and Biophysical Research Communications 1995; 213: 96-103.
45. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000; 57: 100-5.
46. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. J Neuropath Exp Neurol 2007; 66: 264-71.
47. Devanand DP, Schupf N, Stern Y, et al. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. Neurol 2011; 77: 125-31.
48. Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging 2011; 32: S10-S19.
49. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma A-[beta]42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am Geriatric Ps 2005; 13: 914-7.
50. Schupf N, Tang MX, Fukuyama H, et al. Peripheral A[beta] subspecies as risk biomarkers of Alzheimer's disease. PNAS 2008; 105: 14052-7.
51. Strozyk D, Blennow K, White LR, Launer LJ. CSF A{beta} 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurol 2003; 60: 652-6.
52. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid. Ann Neurol 2006; 59: 512-9.
53. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
54. Engelborghs S, Le BN. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol Diagn Ther 2012; 16: 135-41.
55. Ibach B, Binder H, Dragon M, et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an agematched random sample. Neurobiol Aging 2006; 27: 1202-11.
56. Thaweepoksomboon J, Senanarong V, Poungvarin N, et al. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. J Med Assoc Thai 2011; 94: S77-S83.
57. Agren-Wilsson A, Lekman A, Sjoberg W, et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand 2007; 116: 333-9.
58. Koedam EL, van der Vlies AE, van der Flier WM, et al. Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Alzheimers Dement 2012 Jul 28. [Epub ahead of print]
59. Spies PE, Slats D, Sjogren JM, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 2010; 7: 470-6.
60. Bibl M, Esselmann H, Mollenhauer B, et al. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem 2007; 103: 467-74.
61. Gomis M, Sobrino T, Ois A, et al. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke 2009; 40: 3197-201.
62. Gurol ME, Irizarry MC, Smith EE, et al. Plasma {beta}-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurol 2006; 66: 23-9.
63. van Dijk EJ, Prins ND, Vermeer SE, et al. Plasma amyloid b, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004;55:570-5.
64. Hernandez-Guillamon M, Delgado P, Penalba A, et al. Plasma betaamyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis 2012; 10: 320-3.
65. Sun X, Bhadelia R, Liebson E, et al. The relationship between plasma amyloid-beta peptides and the medial temporal lobe in the homebound elderly. Int J Geriatr Psychiatry 2011; 26: 593-601.
66. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-9.
67. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study MRC C. Pathological correlates of lateonset dementia in a multicentre, community-based population in England and Wales. The Lancet 2001; 357: 169-75.
68. Bibl M, Welge V, Schmidt H, et al. Plasma Amyloid-BetaPeptides in Acute Cerebral Ischemia: A Pilot Study. J Clin Lab Anal 2012; 26: 238-45.
69. Cirrito RJ, Yamada AK, Finn MB, et al. Synaptic Activity Regulates Interstitial Fluid Amyloid-B Levels in vivo. Neuron 2005; 48: 913-22.
70. Pomara N, Doraiswamy PM, Willoughby LM, et al. Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res 2006; 31: 341-9.
71. Moon YS, Kang SH, No HJ, et al. The correlation of plasma Abeta42 levels, depressive symptoms, and cognitive function in the Korean elderly. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1603-6.
72. Lee JH, Lee KU, Lee DY, et al. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci 2002; 57: 47-53.
73. Bae JN, Cho MJ. Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients. J Psychosom Res 2004; 57: 297-305.
74. Mayeux R, Honig LS, Tang MX, et al. Plasma A and A 42 and Alzheimer's disease, relation to age, mortality, and risk. Neurol 2003;61:1185-90.
75. Qiu WQ, Sun X, Selkoe DJ, et al. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 2007; 22: 536-42.
76. Sun X, Mwamburi DM, Bungay K, et al. Depression, antidepressants, and plasma amyloid beta (Beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 2007; 62: 1413-7.
77. Sun X, Chiu CC, Liebson E, et al. Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis Assoc Disord 2009; 23: 238-44.
78. Sun X, Steffens DC, Au R, et al. Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease? Arch Gen Psych 2008; 65: 542-50.
79. Radloff LW. The CES-D scale: A self report depression scale for research in the general population. Applied Psychological Measurement 1977; 1: 385.
80. Kita Y, Baba H, Maeshima H, Nakano Y, Suzuki T, Arai H. Serum amyloid beta protein in young and elderly depression: a pilot study. Psychogeriatrics 2009; 9: 180-5.
81. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
82. Baba H, Nakano Y, Maeshima H, et al. Metabolism of amyloidbeta protein may be affected in depression. J Clin Psychiatry 2012; 73: 115-20.
83. Metti AL, Cauley JA, Newman AB, et al. Plasma Beta Amyloid Level and Depression in Older Adults. J Gerontol A Biol Sci Med Sci 2012; 68: 74-9
84. Blasko I, Kemmler G, Jungwirth S, et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry 2010; 18: 973-82.
85. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med 1994; 10: 77-84.
86. Hock C, Golombowski S, Muller-Spahn F, et al. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression-inverse correlation with dementia severity. Eur Neurol 1998; 39: 111-8.
87. Sjogren M, Minthon L, Davidsson P, et al. CSF levels of tau, betaamyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107: 563-79.
88. Pomara N, Bruno D, Sarreal ASHRT, et al. Cerebrospinal fluid amyloid beta levels are lower and F2-isoprostanes higher in individuals with major depressive disorder. Am J Psychiat 2012; 169: 523-30.
89. Osorio RS, Basireddy S, Sadda R, et al. Metabolism of CSF betaamyloid 42 is affected by vascular risk factors, memory and depressive symptoms differently in cognitively normal APOE4 carriers. Alzheimers Dement 2012; 8(4): 268-9.
90. Gudmundsson P, Skoog I, Waern M, et al. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 2007; 15: 832-8.
91. Montgomery SA, Smeyatsky N, de RM, Montgomery DB. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand Suppl 1985; 320: 38-42.
92. Kramberger MG, Jelic V, Kareholt I, et al. Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease. Dement Geriatr Cogn Dis Extra 2012; 2: 48-56.
93. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for depression in dementia. Biological Psychiatry 1988; 23: 271-84.
94. Ye S, Huang Y, Mullendorff K, et al. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci USA 2005; 102: 18700-5.
95. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med 2011; 49: 375-83.
96. Holtzman DM, Bales KR, Wu S, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999; 103: R15-R21.
97. Fagan AM, Younkin LH, Morris JC, et al. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000; 48: 201-10.
98. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurol 2004; 62: 2116-8.
99. Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004; 56: 670-6.
100. Shoji M, Kanai M. Cerebrospinal fluid Abeta40 and Abeta42: Natural course and clinical usefulness. J Alzheimers Dis 2001; 3: 313-21.
101. Kester MI, Blankenstein MA, Bouwman FH, Van Elk EJ, Scheltens P, van der Flier WM. CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. J Alzheimers Dis 2009; 16: 601-7.
102. Glodzik-Sobanska L, Pirraglia E, Brys M, et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiology Aging; 30: 672-81.
103. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13.
104. Scott TM, Peter I, Tucker KL, et al. The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psychiatry 2006; 21: 519-28.
105. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619-27.
106. Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-34.
107. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65.
108. Butters MA, Klunk WE, Mathis CA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord 2008; 22: 261-8.
109. Madsen K, Hasselbalch BJ, Frederiksen KS, et al. Lack of association between prior depressive episodes and cerebral [(11)C]PiB binding. Neurobiol Aging 2012; 33: 2334-42.
110. Tsopelas C, Stewart R, Savva GM, et al. Neuropathological correlates of late-life depression in older people. Br J Psychiatry 2011; 198: 109-14.
111. Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on abeta dynamics in the human central nervous system. Arch Neurol 2012; 69: 51-8.
112. Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009 13; 326: 1005-7.
113. Sloan EP, Flint AJ, Reinish L, Shapiro CM. Circadian rhythms and psychiatric disorders in the elderly. J Geriatr Psychiatry Neurol 1996; 9: 164-70.
114. Souetre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989; 28: 263-78.
115. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008; 23: 571-85.